Effect of Propranolol on Serum Free T4 and Free T3 in Healthy Subjects

1984 ◽  
Vol 66 (2) ◽  
pp. 69P-69P
Author(s):  
M.R. Wilkins ◽  
J.A. Franklyn ◽  
K.L. Woods ◽  
M.J. Kendall
Keyword(s):  
Healthy Subjects ◽  
Free T4 ◽  
Serum Free ◽  
Free T3

Effect of Propranolol on Serum Free T4 and Free T3 in Healthy Subjects:

1984 ◽  
Vol 66 (6) ◽  
pp. 69P.1-69P
Author(s):  
M.R. Wilkins ◽  
J.A. Franklyn ◽  
K.L. Woods ◽  
M.J. Kendall
Keyword(s):  
Healthy Subjects ◽  
Free T4 ◽  
Serum Free ◽  
Free T3

Comparison of a new ultrafiltration method for serum free T4 and free T3 with two RIA kits in eight groups of patients

1985 ◽  
Vol 8 (6) ◽  
pp. 495-500 ◽  
Author(s):  
Yuh-Shyun Wang ◽  
A. E. Pekary ◽  
M. L. England ◽  
Jerome M. Hershman
Keyword(s):  
Free T4 ◽  
Serum Free ◽  
Free T3

A comparison of measurements of serum free T3 concentration by equilibrium dialysis, free T3 index, and T3: TBG ratio in thyroidal and non-thyroidal illnesses

1983 ◽  
Vol 103 (4) ◽  
pp. 501-508 ◽  
Author(s):  
Norimichi Konno ◽  
Takashi Nakazato ◽  
Kohji Hagiwara ◽  
Hideo Taguchi
Keyword(s):  
Serum Concentration ◽  
Healthy Subjects ◽  
Equilibrium Dialysis ◽  
Indirect Measure ◽  
Serum Free ◽  
Free T3 ◽  
Low Serum

Abstract. The present study was undertaken and compare the methods for measuring free T3 (FT3) by equilibrium dialysis, free T3 index (FT3I), and T3:T4-binding globulin (T3/TBG) in 40 healthy subjects, 26 patients with hyperthyroidism, 36 patients with hypothyroidism, 16 women in the 3rd trimester of pregnancy, 5 euthyroid subjects with low TBG, and 24 patients with non-thyroidal illnesses (NTI) with normal or low serum T3 concentration. Both FT3I and T3/TBG correlated significantly with FT3 (r = 0.98, P < 0.001 and r = 0.92, P< 0.001, respectively) when the data from all subjects were analyzed together. When each group was analyzed separately, FT3I still correlated significantly with FT3 in all groups (r = 0.67–0.97) except in the NTIs with low T3 (r = 0.18). The correlation of T3/TBG with FT3 was also significant in all groups (r = 0.60–0.88) other than the euthyroid with low TBG (r = 0.32) and NTIs with low T3 (r = 0.04). Both FT3I and T3/TBG values agreed well with the FT3 level in hyper- and hypothyroid subjects. In euthyroidism with abnormal TBG level, FT3I agreed well with FT3. However, T3/TBG gave a falsely lower FT3 when the TBG level was high, and a falsely higher FT3 when the TBG was low. In NTIs with normal T3, both FT3I and T3/TBG agreed well with FT3, but FT3I and T3/TBG values were all subnormal in NTIs with low T3, where FT3 ranged from normal to subnormal. These data suggest that 1) both FT3I and T3/TBG may be equally useful for an assessment of FT3 level in hyperand hypothyroidism, 2) FT3I may be superior to T3/TBG in euthyroidism with abnormal TBG concentration in serum, and 3) neither FT3I nor T3/TBG may be valid for an indirect measure of FT3 in NTIs with low serum concentration of T3.

scholarly journals Diverse Genotypes and Phenotypes of Three Novel Thyroid Hormone Receptor-α Mutations

2016 ◽  
Vol 101 (8) ◽  
pp. 2945-2954 ◽  
Author(s):  
Korcan Demir ◽  
Anja L. M. van Gucht ◽  
Muammer Büyükinan ◽  
Gönül Çatlı ◽  
Yavuz Ayhan ◽  
...  
Keyword(s):  
Thyroid Hormone ◽  
Motor Development ◽  
Thyroid Hormone Receptor ◽  
Clinical Phenotype ◽  
Case Series ◽  
Detailed Knowledge ◽  
Thyroid Function Tests ◽  
Free T4 ◽  
Serum Free ◽  
Free T3

Context: Recently several patients with resistance to thyroid hormone (RTH)-α due to T3 receptor-α (TRα) mutations were identified. The phenotype of these patients consists of varying degrees of growth impairment, delayed bone, mental and motor development, constipation, macrocephaly, and near-normal thyroid function tests. Objective: The objective of the study was to describe the clinical phenotype of three new families with RTHα and thereby gain more detailed knowledge on this novel syndrome. Design, Setting, and Participants: RTHα was suspected in three index patients from different families. Detailed clinical and biochemical assessment and imaging and genetic analyses were performed in the patients and their relatives. In addition, functional consequences of TRα mutations were investigated in vitro. Results: We studied 22 individuals from three families and identified 10 patients with heterozygous TRα mutations: C380fs387X, R384H, and A263S, respectively. The frame-shift mutation completely inactivated TRα, whereas the missense mutations produced milder defects. These mutations were associated with decreasing severity of the clinical phenotype: the patient in family 1 showed severe defects in growth, mental, and motor development, whereas the seven patients in family 3 had only mild clinical features. The most frequent abnormalities were anemia, constipation, and a delay in at least one of the developmental milestones. Serum free T3 ranged from high-normal to high and serum free T4 and rT3 from normal to low. TSH levels were normal in all patients. Conclusions: This large case series underlines the variation in the clinical phenotype of RTHα patients. RTHα should be suspected in subjects when even mild clinical and laboratory features of hypothyroidism are present along with high/high-normal free T3, low/normal free T4, and normal TSH.

scholarly journals Is a Normal TSH Synonymous With “Euthyroidism” in Levothyroxine Monotherapy?

2016 ◽  
Vol 101 (12) ◽  
pp. 4964-4973 ◽  
Author(s):  
Sarah J. Peterson ◽  
Elizabeth A. McAninch ◽  
Antonio C. Bianco
Keyword(s):  
Large Population ◽  
Density Lipoprotein ◽  
Free T4 ◽  
Lower Serum ◽  
Cross Sectional ◽  
Serum Free ◽  
Free T3 ◽  
Metabolic Equivalents ◽  
Serum T3 ◽  
Serum Tsh

Context: Levothyroxine (LT4) monotherapy is the standard of care for hypothyroidism. Objective: To determine whether LT4 at doses that normalize the serum TSH is associated with normal markers of thyroid status. Design: Cross-sectional data from the US National Health and Nutrition Examination Survey (2001–2012) was used to evaluate 52 clinical parameters. LT4 users were compared to healthy controls and controls matched for age, sex, race, and serum TSH. Regression was used to evaluate for correlation with T4 and T3 levels. Participants: A total of 9981 participants with normal serum TSH were identified; 469 were LT4-treated. Results: Participants using LT4 had higher serum total and free T4 and lower serum total and free T3 than healthy or matched controls. This translated to approximately 15–20% lower serum T3:T4 ratios in LT4 treatment, as has been shown in other cohorts. In comparison to matched controls, LT4-treated participants had higher body mass index despite report of consuming fewer calories/day/kg; were more likely to be taking beta-blockers, statins, and antidepressants; and reported lower total metabolic equivalents. A serum TSH level below the mean in LT4-treated participants was associated with a higher serum free T4 but similar free and total T3; yet those with lower serum TSH levels exhibited higher serum high-density lipoprotein and lower serum low-density lipoprotein, triglycerides, and C-reactive protein. Age was negatively associated with serum free T3:free T4 ratio in all participants; caloric intake was positively associated in LT4-treated individuals. Conclusions: In a large population study, participants using LT4 exhibited lower serum T3:T4 ratios and differed in 12/52 objective and subjective measures.

scholarly journals Factors influencing serum free T3 and free T4 in elderly euthyroid sujbects.

1989 ◽  
Vol 26 (4) ◽  
pp. 401-406 ◽  
Author(s):  
Yoriko Shimamoto ◽  
Hiroyuki Shimamoto ◽  
Hideo Nakamura
Keyword(s):  
Free T4 ◽  
Serum Free ◽  
Free T3 ◽  
Factors Influencing

scholarly journals Cardiac Effects of Thyrotropin Oversuppression with Levothyroxine in Young Women with Differentiated Thyroid Cancer

2016 ◽  
Vol 2016 ◽  
pp. 1-6 ◽  
Author(s):  
Kyung-Soon Hong ◽  
Jung-Woo Son ◽  
Ohk Hyun Ryu ◽  
Moon-Gi Choi ◽  
Ji Yeon Hong ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Differentiated Thyroid Cancer ◽  
Thyroid Stimulating Hormone ◽  
Suppressive Therapy ◽  
Fixed Dose ◽  
Free T4 ◽  
Serum Free ◽  
Cardiac Effects ◽  
Free T3 ◽  
Cardiac Functions

Background. We investigated the cardiac effects of TSH (thyroid-stimulating hormone) oversuppression in women with thyroidectomized differentiated thyroid cancer (DTC) during levothyroxine suppression therapy.Methods. Fourteen young female patients with DTC were enrolled. The duration of TSH-suppressive therapy was 5 to 9 years. They satisfied the following criteria: (1) a serum level of TSH < 0.1 mU/L in the intermediate-risk or TSH < 0.3 mU/L in the low-recurrence-risk group and (2) having been receiving a fixed dose of LT4 before the study. Controls matched for age, sex, and body mass index (BMI) were compared in terms of the levels of serum free T4, free T3, TSH, plasma N-terminal pro-brain natriuretic peptide (NT-pro-BNP), and cardiac functions and structures.Results. DTC patients and control subjects were well matched in heart rate and blood pressure. There were marked differences in serum TSH (P=0.001) and free T4 (P=0.002). However, there were no differences between the groups in serum free T3 and plasma NT-pro-BNP. Furthermore, there were nonsignificant differences in cardiac functions and structures between the groups.Conclusions. This study shows that TSH suppression therapy in women with DTC may be safe with respect to cardiac functions and structures despite intermittent oversuppression of TSH during long-term suppressive therapy.Trial Registration. This trial is registered with clinicaltrials.gov identifierNCT02645786.

Sign in / Sign up

Export Citation Format

Share Document